News from asieris A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 11, 2020, 04:08 ET Asieris Announces First Patient Administration in the Global Phase III Clinical Trial for APL-1702

Asieris Pharmaceuticals, a China-based biotech company with global aspirations to discover, develop, and commercialize innovative drugs for the...


Nov 05, 2020, 00:59 ET Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC)

Asieris Pharmaceuticals (Asieris), a China-based biotech company specializing in the development and commercialization of new drugs for the treatment ...


Oct 28, 2020, 21:17 ET Asieris' APL-1501 Approved for Phase I Clinical Trial in Australia

Asieris Pharmaceuticals, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of...


Jul 08, 2020, 10:00 ET Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)

Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for...


Dec 19, 2019, 09:00 ET Asieris Wins Questex's Fierce Innovation Awards - Life Sciences Edition 2019

Asieris, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors...


Jul 02, 2019, 09:40 ET Asieris and Photocure Enter into a License Agreement for World-Wide Development and Commercialization of Cevira®

Asieris MediTech Co, Ltd (Asieris), a China-based biotech company specializing in the development and commercialization of new drugs for the...


Jun 24, 2019, 09:40 ET Asieris Announces Completion of Enrollment for its US APL-1202 Phase Ib Clinical Trial

Asieris, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors...